NCT03278964 is a NA clinical trial of Orbital decompression in Graves Ophthalmopathy, sponsored by University of Sao Paulo General Hospital.

Who is sponsoring NCT03278964?

NCT03278964 is sponsored by University of Sao Paulo General Hospital.

What drugs are being tested in NCT03278964?

Interventions in NCT03278964: Orbital decompression.

What condition does NCT03278964 study?

NCT03278964 studies Graves Ophthalmopathy.

Is NCT03278964 still recruiting?

NCT03278964 is currently completed. Last updated 13 August 2019.

Last reviewed 2019-08-13 · How we verify

NCT03278964

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy

Completed NA Last updated 13 August 2019

What this trial tests

NA trial testing Orbital decompression in Graves Ophthalmopathy in 42 participants. Completed in 31 January 2019.

Timeline

5 February 2015

Primary endpoint
31 January 2019

31 January 2019

Quick facts

Lead sponsor	University of Sao Paulo General Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	42
Start date	5 February 2015
Primary completion	31 January 2019
Estimated completion	31 January 2019
Sites	1 location across Brazil

Drugs / interventions tested

Orbital decompression

Conditions studied

Graves Ophthalmopathy — all drugs for Graves Ophthalmopathy →

Sponsor

University of Sao Paulo General Hospital

Who can join

21 and older, any sex, with Graves Ophthalmopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized prospective clinical trial, aiming to compare two techniques of orbital decompression. Patients with Graves orbitopathy in the inactive phase for at least 6 months will be divided in two groups; one group will be submitted to orbital decompression by antro-ethmoidal technique; the other group will be submitted to orbital decompression by lateral wall technique. Patients will be followed up for a period of 6 months after the surgery, and will be evaluated about the effect of orbital decompression on ocular motility, proptosis, ocular surface and quality of life.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Ocular motility changes after inferomedial wall and balanced medial plus lateral wall orbital decompression in Graves' orbitopathy: a randomized prospective comparative study.
Leite CA, Pereira TS, Chiang J, Moritz RB, et al · · 2021 · cited 11× · PMID 33852655 · DOI 10.6061/clinics/2021/e2592
Evaluation of Ocular Versions in Graves' Orbitopathy: Correlation between the Qualitative Clinical Method and the Quantitative Photographic Method.
Leite CA, Pereira TS, Chiang J, Pieroni Gonçalves AC, et al · · 2020 · cited 3× · PMID 32832143 · DOI 10.1155/2020/9758153

Verify or expand the search:

Other recruiting trials for Graves Ophthalmopathy

Currently open trials in the same condition.

NCT07480720 — Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease · recruiting
NCT05126147 — Hydroxychloroquine in Mild Graves' Orbitopathy · Phase 4 · recruiting
NCT06275373 — The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction · recruiting
NCT05678374 — Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease · recruiting
NCT03131726 — Treatment of Graves´ophthalmopathy with Simvastatin (GO-S) · Phase 3 · recruiting

Other University of Sao Paulo General Hospital trials

Trials by the same sponsor.

NCT07275580 — Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
NCT07478094 — Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost · not yet recruiting
NCT07341386 — Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
NCT07242092 — Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs · Phase 4 · not yet recruiting
NCT07484152 — Motor and Non-Motor Effects of Low-Intensity Focused Ultrasound (LIFU) as a Neuromodulation Tool in Essential Tremor · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03278964 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Sao Paulo General Hospital
Last refreshed: 13 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03278964.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing